Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 30-38

  Siegel, Corey A ^a   Siegel, Lori S ^b   Hyams, Jeffrey S ^c   Kugathasan, Subra ^d   Markowitz, James ^e   Rosh, Joel R ^f   Leleiko, Neal ^g   MacK, David R ^h   Crandall, Wallace ⁱ   Evans, Jonathan ^j   Keljo, David J ^k   Otley, Anthony R ^l   Oliva Hemker, Maria ^m   Farrior, Sharmayne ⁿ   Langton, Christine R ^c   Wrobel, Iwona T ^o   Wahbeh, Ghassan ^p   Quiros, J Antonio ^q   Silber, Gary ^r   Bahar, Ron J ⁿ   Sands, Bruce E ^s   Dubinsky, Marla C ⁿ   more..

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Siegel Environmental Dynamics LLC   (United States)

^c Farmington   (United States)

^d EMORY UNIVERSITY   (United States)

^e SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^f MORRISTOWN MEMORIAL HOSPITAL   (United States)

^g HASBRO CHILDREN'S HOSPITAL   (United States)

^h CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

ⁱ NATIONWIDE CHILDREN S HOSPITAL   (United States)

^j NEMOURS CHILDREN S CLINIC   (United States)

^k CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^l DALHOUSIE UNIVERSITY   (Canada)

^m JOHNS HOPKINS HOSPITAL   (United States)

ⁿ CEDARS SINAI MEDICAL CENTER   (United States)

^o ALBERTA CHILDREN'S HOSPITAL   (Canada)

^p SEATTLE CHILDREN S HOSPITAL   (United States)

^q CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^r Phoenix Children's Hospital   (United States)

^s MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

complication; Crohn's; model; pediatric; prediction

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; MERCAPTOPURINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANALYTIC METHOD; ANUS DISEASE; ARTICLE; CHILD; CHILDHOOD DISEASE; CROHN DISEASE; DECISION MAKING; DISEASE COURSE; FEMALE; HUMAN; IMMUNE RESPONSE; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SEROLOGY; SEX DIFFERENCE; SMALL INTESTINE DISEASE; SYSTEM DYNAMIC ANALYSIS; TREATMENT RESPONSE; VALIDATION PROCESS;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INFANT; MALE; MODELS, STATISTICAL; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650077217     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21386     Document Type: Article

References (15)

1. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005; 54: 237-241.
2. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371: 660-667.
3. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007; 132: 863-873; quiz 1165-1166.
4. Sandborn W, Rutgeerts P, Reinisch W, et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Am J Gastroenterol. 2008; 103: S436.
5. Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007; 133: 769-779.
6. Johnson FR, Ozdemir S, Mansfield C, et al. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal. 2009; 29: 121-136.
7. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008; 6: 1105-1111.
8. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology. 2006; 130: 650-656.
9. Ford A,. Modeling the environment: an introduction to system dynamics modeling of environmental systems. Washington, DC: Island Press, 1999.
10. Jones AP, Homer JB, Murphy DL, et al. Understanding diabetes population dynamics through simulation modeling and experimentation. Am J Public Health. 2006; 96: 488-494.
11. Harrell FE,. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. Berlin: Springer; 2001; p 87-287.
12. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000; 119: 895-902.
13. Henckaerts L, Verstreken I, Van Steen K, et al. NOD2/CARD15 and risk of complicating disease behavior in Crohn's disease. Gastroenterology. 2007; 132: A-17.
14. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007; 56: 1394-1403.
15. Lipkus IM,. Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Making. 2007; 27: 696-713.